Difference between revisions of "MOC31"

From Libre Pathology
Jump to navigation Jump to search
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
'''MOC31''' is an [[immunostain]].
'''MOC31''' is an [[immunostain]]. The antibody is directed against the epithelial cell adhesion molecule (Ep-CAM, TACSTD1).<ref name=pmid19391212/>
 
It is useful for differentiating [[hepatocellular carcinoma]] from [[cholangiocarcinoma]] and [[liver metastases]].<ref name=pmid10937059>{{Cite journal  | last1 = Proca | first1 = DM. | last2 = Niemann | first2 = TH. | last3 = Porcell | first3 = AI. | last4 = DeYoung | first4 = BR. | title = MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. | journal = Appl Immunohistochem Mol Morphol | volume = 8 | issue = 2 | pages = 120-5 | month = Jun | year = 2000 | doi =  | PMID = 10937059 }}</ref>


==Negative==
==Negative==
*[[Hepatocellular carcinoma]].<ref name=pmid10937059/>
*[[Hepatocellular carcinoma]].<ref name=pmid10937059>{{Cite journal  | last1 = Proca | first1 = DM. | last2 = Niemann | first2 = TH. | last3 = Porcell | first3 = AI. | last4 = DeYoung | first4 = BR. | title = MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. | journal = Appl Immunohistochem Mol Morphol | volume = 8 | issue = 2 | pages = 120-5 | month = Jun | year = 2000 | doi =  | PMID = 10937059 }}</ref>
*[[Malignant mesothelioma|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/>
*[[Malignant mesothelioma|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/>


Line 16: Line 14:
==See also==
==See also==
*[[Immunohistochemistry]].
*[[Immunohistochemistry]].
*[[Ber-EP4]].


==References==
==References==

Latest revision as of 16:30, 15 May 2016

MOC31 is an immunostain. The antibody is directed against the epithelial cell adhesion molecule (Ep-CAM, TACSTD1).[1]

Negative

Positive

See also

References

  1. 1.0 1.1 1.2 Pai, RK.; West, RB. (May 2009). "MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study.". Appl Immunohistochem Mol Morphol 17 (3): 202-6. PMID 19391212.
  2. 2.0 2.1 2.2 Proca, DM.; Niemann, TH.; Porcell, AI.; DeYoung, BR. (Jun 2000). "MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.". Appl Immunohistochem Mol Morphol 8 (2): 120-5. PMID 10937059.
  3. 3.0 3.1 Ordóñez, NG. (Feb 1998). "Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.". Hum Pathol 29 (2): 166-9. PMID 9490276.